Passage: The company said Saturday that it was in the process of notifying all clinical investigators and regulatory authorities, including the Food and Drug Administration. The decision comes after Pfizer officials were informed that the independent Data Safety Monitoring Board (DSMB) reviewing a morbidity and mortality study for Torcetrapib recommended terminating the trial "because of an imbalance of mortality and cardiovascular events."
recommended